PhagoMed Biopharma GmbH is a pre-clinical biotech company focused on accelerating the re-introduction of phage therapy into Western medical practice. PhagoMed builds on the treatment expertise of its co-founders Prof. Dr. Wippermann and PD Dr. Trampuz, who have jointly treated ~20 patients with bacteriophages as a last resort over the past 15 years. As of early 2018, PhagoMed has completed its seed financing round (private investment
R&D:PhagoMed focuses on bacteriophage applications in areas of high medical need, where antibiotics typically fail. The lead indication is the field of periprosthetic infections, a devastating and hard-to-treat indication. Together with the research partners at Charité in Berlin, PhagoMed has shown that phages act synergistically with antibiotics to kill the biofilm that typically forms in these infections. PhagoMed is also active in the field of Urogenital Infections.